Medegen has announced that it is pursuing an appeal in the Federal Circuit in Washington, District of Columbia, of a judgment of patent non-infringement entered in favor of ICU Medical by a district court judge in the Central District of California.
Subscribe to our email newsletter
Medegen continues to believe that ICU’s valve product, CLC-2000, infringes on the company’s patent for its proprietary valve technology. This patent covers a number of Medegen’s novel inventions in luer-activated valves, including the use of positive displacement technology, which reduces the occurrence of common vascular access device-related complications.
Jeffrey Goble, president of Medegen, said: “Medegen’s intellectual property is valuable and we feel strongly about protecting our innovations and are confident we will prevail in the appeal process.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.